Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NovoCare Pharmacy vs Pomegranate Health

NovoCare Pharmacy
Graded #442

Lower grade

vs+14.200000000000003
Pomegranate Health
Graded #122

Higher grade

The verdict

Pomegranate Health takes it — 69.4/100 to 55.2/100.

Pomegranate Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Pomegranate Health sells compounded semaglutide and tirzepatide with no membership and no consultation fee.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePomegranate Health +56
24
80
Dose & formulationNovoCare Pharmacy +2
66
64
Clinical oversightPomegranate Health +8
74
82
Labs & monitoringPomegranate Health +2
51
53
FulfillmentNovoCare Pharmacy +11
76
65
Contract termsEven
55
55
NovoCare Pharmacy · left barPomegranate Health · right bar

The numbers

MetricNovoCare PharmacyPomegranate Health
WeighScore55.2/10069.4/100
GradeCC
Scorecard rank#442#122
Semaglutide$349/mo (2.4 mg dose, brand-name)$119/mo (starting price, compounded)
TirzepatideNot disclosed$149/mo (Starter tier, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
NovoCare Pharmacy

Graded #442 · C

Strengths

  • First-party Novo Nordisk pharmacy — the most authoritative branded Wegovy channel
  • $199/mo intro pricing on Wegovy 0.25/0.5 mg starter doses (through 6/30/2026), the lowest brand self-pay price
  • $349/mo standard self-pay is well below the ~$1,300/mo retail list price
  • Ships to all 50 states with no telehealth-platform middleman fees
  • Cold-chain logistics handled directly by Novo Nordisk

Where it loses points

  • Wegovy only — no Ozempic, no tirzepatide, no compounded GLP-1
  • Requires an existing Wegovy prescription — no prescribing clinicians or telehealth intake
  • No clinical support included — your own prescriber handles titration and side effects
  • Manufacturer-set pricing can change at any time
  • $199 pen intro covers only the first 2 fills for new patients (through 6/30/2026); maintenance doses are $349/mo ($399 HD)
Pomegranate Health

Graded #122 · C

Strengths

  • No membership and no consultation fee — the site states 'No Membership required' and 'Transparent pricing, no hidden fees'
  • The semaglutide price sits in the product page's own static HTML, so it can be read before any intake
  • Shipping is included: 'shipped discreetly to your door at no extra cost'
  • Both semaglutide and tirzepatide are offered

Where it loses points

  • The tirzepatide price is not on the public site at all — it exists only inside the in-app pricing portal, and there is no standalone tirzepatide product page to read it from
  • Both published figures are floors, a 'Starts @' and a Starter tier, and no price is published for the dose you titrate up to
  • The states it can prescribe in are not disclosed anywhere; the dataset's own note records that semaglutide was unavailable in CA, IA and WI
  • Klarna, Afterpay and Affirm are offered at checkout, so any monthly figure seen in a financing widget is an instalment and not the medication price
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard